Frontier Biosciences Signs Agreement With Top China-Based Preclinical CRO

Frontier BioSciences, Inc announced it has signed a formal agreement with the National Chengdu Center for Safety Evaluation of Drugs (NCCSED) to become shareholder and strategic partner in the preclinical contract research service business.

NCCSED was established in 2000 by West China Hospital (WCH) of Sichuan University.

Since its inception, this full service preclinical contract research laboratory has become one of the top drug safety evaluation centers in China having received GLP certification by China’s State Food and Drug Administration (SFDA) in 2004.

The NCCSED has also been awarded multiple grants from the Ministry of Sciences and Technologies of China. Covering an area of 80,000 sq. ft., this state-of-the-art toxicology facility is comprised of a small SPF animal facility and a conventional large animal facility.

It is equipped with the latest advanced technology and operated by experienced staff with international CRO experience. It has conducted safety and efficacy studies for more than 60 preclinical candidates in the past three years.

“With the NCCSED’s extensive preclinical toxicology experience and unblemished reputation, along with Frontier’s US-trained technical and quality assurance staff, we are poised to provide high-quality and cost-effective services to our customers. We are committed to being a global partner and assisting our customers to move product candidates toward clinic and marketplace”, said Frontier’s President, Dong Xie, Ph.D.

Said NCCSED’s Director, Li Wang, Ph.D., “With the full technical support of WCH, the largest hospital in Asia with comprehensive teaching and research facility for all medical disciplines, the new partnership will bring online a wide range of preclinical and clinical drug development services, while delivering speed, quality, and economy at international standard.”